文献速递头颈外科

人乳头状瘤病毒阳性口咽鳞状细胞癌中辅助治疗遗漏情况分析

Missed Adjuvant Therapy in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma.
PubMed 文献 · Laryngoscope · 2024-10-08

基于2010—2017年美国国家癌症数据库,纳入5297例手术切除的HPV阳性口咽鳞癌患者,分析辅助放疗或放化疗遗漏情况。在有辅助放疗指征者中,未接受辅助治疗与接受辅助治疗的总生存率无显著差异(90.0% vs 94.8% vs 93.4%,p=0.080)。在有辅助放化疗指征者中,仅接受辅助放疗与接受辅助放化疗的总生存率相似(89.0% vs 86.6%,p=0.357),但均优于未接受辅助治疗(74.9%,p<0.001)。

要点

  • 在有辅助放疗指征的HPV阳性口咽鳞癌患者中,遗漏辅助放疗与较差总生存无关。
  • 在有辅助放化疗指征的患者中,仅接受辅助放疗与接受辅助放化疗的总生存率相似。
  • 未接受任何辅助治疗的患者总生存率较低。

核心结论

  • 在有辅助放疗指征的HPV阳性口咽鳞癌患者中,遗漏辅助放疗与较差总生存无关。
  • 在有辅助放化疗指征的患者中,仅接受辅助放疗与接受辅助放化疗的总生存率相似。

研究设计与样本

  • 回顾性查询2010—2017年美国国家癌症数据库,纳入手术切除的HPV阳性口咽鳞癌患者5297例,采用多变量逻辑回归和Cox回归模型。

主要发现

  • 5297例患者中4288例有辅助放疗指征,其中775例未接受任何辅助治疗,视为遗漏辅助放疗。
  • 2234例有辅助放化疗指征,其中1383例(61.9%)接受辅助放化疗,555例(24.8%)仅接受辅助放疗视为遗漏辅助放化疗,296例(13.2%)未接受任何辅助治疗。
  • 遗漏辅助放疗和遗漏辅助放化疗均与年龄、治疗机构类型、pN分类和手术切缘状态相关(p<0.015)。
  • 在仅有辅助放疗指征的患者中,未接受辅助治疗、仅接受辅助放疗和接受辅助放化疗的总生存率分别为90.0%、94.8%和93.4%(p=0.080)。
  • 在有辅助放化疗指征的患者中,仅接受辅助放疗与接受辅助放化疗的总生存率相似(89.0% vs 86.6%,p=0.357),且均优于未接受辅助治疗(74.9%,p<0.001);多变量Cox回归中该模式持续存在。

关键数值与推荐

  • 辅助放疗指征包括pT3-4分类、pN2-3分类、淋巴血管侵犯、病理结外延伸(pENE)和/或手术切缘阳性(PSM)。
  • 辅助放化疗指征包括pENE和/或PSM。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate missed adjuvant therapy and associated disparities in overall survival (OS) for human papillomavirus-associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). METHODS: The 2010-2017 National Cancer Database was queried for patients with surgically resected HPV+ OPSCC. Indications for adjuvant radiotherapy (aRT) included pT3-4 classification, pN2-3 classification, lymphovascular invasion, pathologic extranodal extension (pENE), and/or positive surgical margins (PSM). Indication(s) for adjuvant chemoradiotherapy (aCRT) included pENE and/or PSM. Multivariable logistic and Cox regression models were implemented. RESULTS: Of 5297 patients satisfying inclusion criteria, 4288 had indication(s) for aRT; 775 did not receive any adjuvant therapy and were considered as missing aRT. A total of 2234 patients had indication(s) for aCRT. Of these, 1383 (61.9%) received aCRT, 555 (24.8%) patients received aRT alone and were considered as having missed aCRT, and 296 (13.2%) did not receive any adjuvant therapy. Missed aRT and missed aCRT were each associated with age, treatment facility type, pN classification, and surgical margin status (p < 0.015). Among patients with indication(s) for aRT alone, OS of those receiving no adjuvant therapy, aRT alone, and aCRT was 90.0%, 94.8%, and 93.4%, respectively (p = 0.080). Among patients with indication(s) for aCRT, those receiving aRT alone and aCRT had similar OS (89.0% vs. 86.6%, p = 0.357) which was superior to receiving no adjuvant therapy (74.9%, p < 0.001). These patterns in OS persisted on multivariable Cox regression. CONCLUSION: Among patients with HPV+ OPSCC and indication(s) for aRT, missed aRT was not associated with worse OS. For patients with indication(s) for aCRT, aRT alone was associated with similar OS as aCRT. LEVEL OF EVIDENCE: 3 Laryngoscope, 135:729-740, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Huang L, Patel AM, Haleem A, et al. Missed Adjuvant Therapy in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma. Laryngoscope. 2024. PMID: 39377215. doi:10.1002/lary.31823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。